Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB226 in relapsed or metastatic thymic carcinoma after platinum failure
CTR20181434Phase 2Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of geptanolimab in thymic carcinoma (TC), sponsored by Jacobio Pharmaceuticals. Started Dec 2018; status: active.
02
Drugs
geptanolimab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20181434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181434.